Branded PPI denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny a Branded PPI as Experimental

An "experimental" denial for a branded proton pump inhibitor from Aetna is uncommon but can occur in specific circumstances: the branded PPI may be prescribed for an indication not yet reflected in Aetna's coverage policy, or the request may involve a formulation or delivery mechanism that Aetna has not yet classified as standard of care. It may also arise when a branded PPI has recently received an FDA approval for a new indication and Aetna's policy has not yet been updated to reflect it.

Because PPIs are among the most widely prescribed drug classes, an experimental denial for a branded PPI warrants careful examination of the specific indication cited in the prescription and the denial rationale.

## Federal Appeal Framework

• ACA §2719 / External Review: Available within approximately 4 months (180 days) of denial for most non-grandfathered plans. External review is particularly valuable for experimental denials because independent reviewers apply objective clinical standards and are not limited to Aetna's internal policy classifications. Expedited review is available for urgent clinical situations.
• ERISA §503: Guarantees access to the specific criteria and guidelines Aetna relied upon to classify the treatment as experimental, and a full-and-fair internal review.

## Appeal Process and Timeline

1. Identify the specific basis for the experimental classification — request the exact Aetna policy language and clinical criteria applied. This is essential: a denial based on an unapproved indication differs from one based on a novel formulation. 2. Confirm FDA approval status for the specific indication — verify that the branded PPI is FDA-approved for the indication stated in the prescription. The FDA labeling (package insert) is the authoritative source. 3. Internal appeal — respond point-by-point to each basis cited. Standard turnaround is up to 30 days; urgent is 72 hours. 4. External review — if the internal appeal is denied, request independent review. External reviewers frequently overturn experimental denials where FDA approval exists and professional-society guidelines support use.

## Documentation to Gather

• FDA approval for the specific indication: The FDA-approved prescribing information (package insert) for the branded PPI, confirming approval for the indication being treated.
• Diagnosis and clinical documentation: Chart notes establishing the specific GI condition and its severity.
• Professional-society guideline support: A prescriber statement referencing the applicable GI or gastroenterology guideline organization that supports use of this treatment for the diagnosed condition.
• Prior treatment history: Records of prior treatments tried, with dates and outcomes, establishing that this is a clinically appropriate step.
• Prescriber medical-necessity letter: A detailed letter addressing each basis Aetna cited for the experimental classification.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy for the relevant GI indication and the FDA-approved prescribing label for the branded PPI:

| Aetna Experimental Criterion | Rebuttal Evidence | |---|---| | FDA approval status for this indication | [FDA label confirming approval for this indication] | | Evidence-base adequacy per policy | [Prescriber summary of guideline support] | | Diagnosis and indication match | [Chart documentation of confirmed condition] | | Prior standard-of-care treatment history | [Treatment history with dates and outcomes] |

Verify the current version of Aetna's clinical policy before filing. For branded PPIs, the policy language often distinguishes between covered and non-covered indications, and an appeal that addresses the exact indication in the denial is substantially more effective.